According to the study published in journal Science Advance, a team of researchers incorporates CRISPR/HDR along with the Hybridoma technology to boost the process of antibodies production. This could have huge implications for future antibody-based therapeutics and diagnostic techniques. This combination of techniques is highly versatile and the research team believes that it should facilitate mass-scale antibody engineering for the health care sector and scientific community. It will empower preclinical antibody research.
According to the research team, the recent preclinical and clinical studies highlight the importance of antibody isotype for therapeutic efficacy. However, since the sequence encoding the constant domains is fixed, tuning antibody function in hybridomas has been restricted.
Clustered Regularly Interspaced Short Palindrome Repeats (CRISPR) and homology-directed repair (HDR) are two recently developed techniques used for alteration. By integrating both the techniques with Hybridoma Technology, a new method is developed that allows for the rapid engineering of constant immunoglobulin domains to obtain recombinant hybridomas. These hybridomas secrete antibodies in the desired format, species, or isotope.
During the study, the research team used CRISPR/HDR to form recombinant hybridomas, chimeras, and mutants. The developed hybridomas were able to pump out the monoclonal antibodies (mAb) of a particular type, that have a therapeutic potential and previously revolutionized the treatment of once incurable diseases, like some forms of cancer.
According to the reserchers, using this platform, we obtained recombinant hybridomas secreting Fabandprime; fragments, isotype-switched chimeric antibodies, and Fc-silent mutants. These antibody products are stable, retain their antigen specificity, and display their intrinsic Fc-effector functions in vitro and in vivo. Furthermore, we can site-specifically attach cargo to these antibody products via chemoenzymatic modification.
Need custom market research solution? We can help you with that too.
